Clinical Trials Directory

Trials / Completed

CompletedNCT01263457

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in the UK

Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment

Status
Completed
Phase
Study type
Observational
Enrollment
191 (actual)
Sponsor
Merck KGaA, Darmstadt, Germany · Industry
Sex
All
Age
2 Years – 18 Years
Healthy volunteers
Not accepted

Summary

This is a National, Multicentre, Observational Registry to study Adherence and Long Term Outcomes of Therapy in paediatric subjects using Easypod™ electromechanical device for growth hormone treatment from hospital in the UK and to assess the level of adherence of subject receiving SAIZEN® via Easypod™.

Detailed description

Subjects will be enrolled in a multicenter longitudinal observational registry. Parents/subjects will provide their Informed Consent/assent to upload their data for populationbased analyses and optionally to adhere to a patient adherence support program designed to improve their adherence and, ultimately, clinical outcomes. Adherence data will be primarily derived from the Easypod™ device combined with physician data entry of outcome measures. Data will be collected retrospectively and prospectively. This will allow the establishment of adherence profiles and explore the hypothesis that patient adherence support programs improve adherence and subsequent clinical outcomes. Collected data will be also analyzed in a multinational pooled analysis of comparable national studies. Primary Objective: \- To assess the level of adherence of subjects receiving SAIZEN via easypod™ Secondary Objectives: * To describe the impact of adherence on clinical outcomes for subject receiving SAIZEN via easypod™ * To identify adherence subject profiling * To assess the impact of adherence on Insulin-like Growth Factor 1 (IGF-1) (i.e. above, below or within normal ranges) * To assess the endocrinological profile including Triiodothyronine (T3), Thyroxine (T4), Thyroid-stimulating hormone (TSH), Insulin-like Growth Factor 1 (IGF-1) and Insulin-like Growth Factor-Binding Protein 3(IGFBP-3) levels * Temporal profile of IGF-1 and IGFBP-3 levels

Conditions

Interventions

TypeNameDescription
DEVICEEasypodSaizen (Somatotropin) as per Summary of Product Characteristics administered by easypod

Timeline

Start date
2010-11-30
Primary completion
2015-12-31
Completion
2015-12-31
First posted
2010-12-20
Last updated
2021-05-05

Locations

6 sites across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT01263457. Inclusion in this directory is not an endorsement.